CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
CDT Equity Inc. (Nasdaq: CDT) highlighted a new IP filing by Sarborg Limited applying quantum sampling to disease biology and drug discovery, covering 150 disease networks including Crohn's disease, COPD, and psoriasis. CDT holds 1,290 shares in Sarborg, a 22.7% stake; Sarborg's latest raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.
Key figures
- Sarbong stake shares
- 1290
- Sarborg ownership pct
- 22.7%
- Disease networks screened
- 150
- Sarborg implied valuation
- approximately $709 million fully diluted
- Last round price per share
- $125,000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.